Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

S. Sabatine, Marc; P. Giugliano, Robert; Keech, Anthony; Honarpour, Narimon; D. Wiviott, Stephen; A. Murphy, Sabina; Kuder, Julia; Wang, Huei; Liu, Thomas; M. Wasserman, Scott; Sever, Peter; R. Pedersen, Terje

doi:10.1056/nejmoa1615664

Public

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Published in New England Journal of Medicine • Mar 17, 2017

Authors:

Marc S. Sabatine

Robert P. Giugliano

Anthony Keech

Abstract

BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-bli...

Subject

Evolocumab

Medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!